HHS Releases a Peptide Enforcement Discretion Policy: What It Allows, What It Does Not and What Clinics Should Do
On October 28, 2026 HHS released a draft enforcement discretion policy for compounding six peptides, including BPC-157, published in the Federal Register on October 30 with a two-week comment period. It is not an approval, it is not binding and state law still applies.
Key Highlights
- HHS filed a notice of availability on October 28, 2026, published October 30, for a draft Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with written comments due two weeks after publication, about November 13.
- HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician compounding with a peptide bulk drug substance listed in the policy's Appendix A, and news reports say that list is BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500.
- The notice says the policy creates no rights, is not binding on HHS or the public and may be revisited if a safety signal or product quality issue arises, and enforcement discretion is not approval or a listing on the 503A bulks list.
- Reported conditions include an FDA-registered manufacturer and a certificate of analysis for each batch, FDA career scientists opposed the policy and state law on prescribing, delegation and compounding still governs a clinic.
On October 28, 2026, HHS released the peptide policy we wrote about earlier this month while it was under White House review. We could not read the Wall Street Journal's coverage, so this article rests on the Federal Register notice itself, which we read, and on news reports of the policy document, which we could not open. Where a detail comes from reporting, we say so.
What HHS Released
The Federal Register notice is titled Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. It was filed October 28, 2026, is scheduled for publication on October 30, and is signed by the HHS Secretary as a notice of availability. It describes a draft policy, and the notice invites written comments until two weeks after publication, which is about November 13, 2026.
The notice says that, to expand and improve patient access, HHS does not intend to take enforcement action against a state-licensed pharmacy, a federal facility or a licensed physician compounding a drug product using a peptide bulk drug substance found in the policy's Appendix A. It says FDA's future rulemakings may propose adding some or all of these peptides to the 503A bulks list based on the available evidence, and the policy applies while that list is developed through rulemaking.
Which Peptides and Under What Conditions
The notice itself does not name the peptides, because they are in the Appendix A of the policy document. News reports say the six are BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500, with dosage forms varying by peptide, some limited to injection and others to oral, topical or intranasal use. These are the six the advisory committee voted to recommend in July. Reports also say compounders must use a peptide matching the identity the policy describes, from an FDA-registered manufacturer that follows current good manufacturing practices, with a certificate of analysis for each batch covering identity, purity, potency and contaminants such as endotoxins and heavy metals. One report says patients would need a prescription, and another says an FDA official said the agency lacks authority to enforce some of the pharmacy conditions. We could not confirm these from the policy text.
What the Policy Does Not Do
- It is not an approval: these peptides remain unapproved drugs, and compounded drugs are not reviewed by FDA for safety, effectiveness or quality before they are marketed.
- It is not a bulks list listing: adding a substance to the 503A bulks list requires rulemaking, and the notice says only that future rulemaking may propose adding some or all of these peptides.
- It is not binding: the notice says the policy does not establish any rights for any person and is not binding on HHS or the public, and HHS may revisit it if a safety signal or product quality issue arises.
- It does not override state law: a state's rules on prescribing authority, delegation, supervision, compounding and administration continue to apply.
- It does not cover other peptides or research-use-only products: only the substances in Appendix A fall within it, and reporting says HHS framed the policy as a controlled alternative to research-use-only products from foreign makers.
- It does not make marketing claims safe: the evidence is mostly from animal studies, and claims about recovery, anti-aging or performance have not been established in robust trials.
The Safety Dispute
The policy is contested. FDA reviewers found no human safety studies for several of these peptides and said the BPC-157 trials were too small and too short to establish safety or effectiveness for any proposed use, according to reporting, and FDA career staff reportedly pushed back on the policy. In July, FDA's advisory committee voted to recommend adding six of seven reviewed peptides to the 503A bulks list against the advice of FDA staff scientists, and critics have questioned the makeup of the panel, which reporting says included many members who run wellness, longevity or regenerative medicine clinics. Patients who say they were harmed by unapproved peptides have said their accounts are being overlooked, according to a KFF Health News report.
What a Clinic Should Do Now
- Have the medical director decide: whether any of the six belong on the menu, for which patients and under which protocol, and document the basis.
- Check the pharmacy in writing: that it is state-licensed, that it intends to compound under the policy, where its bulk substance comes from and what certificates of analysis it keeps.
- Check your state: some boards and pharmacy boards may restrict or ignore the policy, and a state's own rules decide what a clinic may prescribe and administer.
- Do not buy research-use-only products for patients: a research chemical is not a compounded prescription drug, and the policy does not make it one.
- Keep marketing within the evidence: avoid claims about outcomes the evidence does not support.
- Consider commenting or watching the docket: the notice invites comments on regulations.gov for about two weeks after publication, and the policy may change.
- Plan the patient message: plain, accurate and the same from every staff member.
What Happens Next
The comment period closes about November 13, 2026, and HHS may revise the policy. FDA's second advisory committee meeting, on GHK-Cu, LL-37, Dihexa, Melanotan II and PEG-MGF, is expected before the end of February 2027 with no date set. Formal listing on the 503A bulks list requires rulemaking and may not finish before 2028. Our earlier articles on the July committee votes, FDA's Category 1 and Category 2 tiers and the FDA compounding calendar are the background.
Where MedGrid Fits
MedGrid keeps a clinic's peptide program tied to the medical director's protocols and to what a partner pharmacy is permitted to compound, so a change like this is handled in the next protocol review. Orders placed through the platform go to partner pharmacies checked against what they may compound, and the decision to offer any peptide stays with the physician.
Frequently Asked Questions
- Are BPC-157 and the other five peptides now legal to compound?: HHS says it does not intend to take enforcement action against covered compounders who meet its conditions, but they remain unapproved, the policy is a draft and it is not a bulks list listing. State law still applies.
- Which peptides are covered?: News reports say BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500, listed in the policy's Appendix A. We could not open the appendix.
- Does the policy cover research-use-only peptides?: No. Reporting says it is meant as a controlled alternative to research-use-only products from foreign makers.
- Can my clinic start offering these peptides?: That depends on your medical director, your state's rules, your pharmacy's status and the final policy. The draft does not decide it for you.
- When is the comment deadline?: Two weeks after Federal Register publication on October 30, 2026, which is about November 13.
This article is general educational information about a draft federal enforcement policy, not legal advice for your specific clinic. We read the Federal Register notice and relied on news reporting for the policy's details because we could not open the policy document itself. The policy is a draft with a comment period, it can change and state rules still apply, so confirm current status with your medical director and licensed counsel before making a sourcing, prescribing or patient-communication decision.
MedGrid MSO provides management services to independently owned practices; it does not practise medicine and does not direct clinical decisions. Requirements vary by state and by service, and change over time — nothing on this page is legal or medical advice. Talk to us or your own counsel before making a structural decision for your clinic.